<p>Vanguard Group Inc.（万得集团）在第四季度增持了 Inari Medical, Inc.（纳斯达克股票代码：NARI - 免费报告）的持股比例，根据该公司最近向证券交易委员会（SEC）提交的文件。该公司在该时期收购了额外的 325,586 股股票后，拥有了 5,038,292 股公司股票。截至最近一次提交给 SEC 的文件，Vanguard Group Inc.拥有 Inari Medical 价值 3.27086 亿美元的股份，占公司总股本的 8.69%。</p>
<p>获取 <strong>Inari Medical</strong> 的警报：</p>
<ul>
<li>5 家增长三位数收益的医疗股</li>
</ul>
<p>其他对冲基金和其他机构投资者最近也增加或减少了对该公司的持股。挪威中央银行在第四季度收购了 Inari Medical 股票的新头寸，价值约 2,949,100 美元。Brown Advisory Inc.在第四季度将其对 Inari Medical 的持股增加了 17.6%。Brown Advisory Inc.现在拥有 1,702,113 股公司股票，价值 1.10501 亿美元，比购买时增加了 255,182 股。Clearbridge Investments LLC 在第四季度购入了 Inari Medical 的新头寸，价值约 1,147,900 美元。Point72 Europe London LLP 在第四季度将其对 Inari Medical 的持股增加了 91.8%。Point72 Europe London LLP 现在拥有 332,202 股公司股票，价值 2,156,700 美元，比购买时增加了 158,997 股。最后，Principal Financial Group Inc.在第四季度增加了对 Inari Medical 的持股，增幅为 23.4%。Principal Financial Group Inc.现在拥有 567,266 股公司股票，价值 3,682,700 美元，比上一季度增加了 107,622 股。对冲基金和其他机构投资者拥有公司股份的 90.98%。</p>
<h2>内部人员活动</h2>
<p>据相关消息，首席财务官 Mitch C. Hill 在 4 月 12 日星期五进行了一笔交易，卖出了公司股票 6,000 股。这些股票的平均价格为 40.96 美元，交易总额为 245,760.00 美元。交易完成后，首席财务官在公司中拥有 181,294 股股票，价值约 7,425,802.24 美元。该交易已在向 SEC 提交的法律文件中披露，可通过 SEC 网站访问。此外，首席财务官 Mitch C. Hill 在 4 月 12 日星期五进行了一笔交易，卖出了公司股票 6,000 股。这些股票的平均价格为 40.96 美元，交易总额为 245,760.00 美元。交易完成后，首席财务官直接持有公司 181,294 股股票，价值 7,425,802.24 美元。该交易已在提交给证券交易委员会的文件中披露，可通过 SEC 网站访问。此外，首席执行官 Andrew Hykes 在 5 月 28 日星期二进行了一笔交易，卖出了公司股票 3,000 股。这些股票的平均价格为 50.00 美元，交易总额为 150,000.00 美元。交易完成后，首席执行官在公司中持有 465,474 股股票，价值约 2,327,370.00 美元。此次交易的披露可在此处找到。内部人员在过去 90 天内共出售了价值 7,514,191 美元的公司股票共 161,224 股。公司内部人员目前持有公司股份的 10.60%。</p>
<h2>分析师设定新的价格目标</h2>
<ul>
<li>在业绩大幅增长后，Integer 可能将走向新高</li>
</ul>
<p>一些研究分析师最近发布了关于 NARI 股票的报告。Truist Financial 将 Inari Medical 的目标股价从 61.00 美元降至 52.00 美元，并在 3 月 22 日的报告中为该公司设定了 “持有” 评级。Canaccord Genuity Group 将 Inari Medical 的目标股价从 75.00 美元降至 55.00 美元，并在 5 月 1 日的报告中为该公司设定了 “买入” 评级。Needham &amp; Company LLC 将 Inari Medical 的目标股价从 72.00 美元降至 57.00 美元，并在 5 月 1 日的研究报告中为该股票设定了 “买入” 评级。富国银行将 Inari Medical 的目标股价从 100.00 美元降至 84.00 美元，并在 5 月 1 日的研究报告中为该公司设定了 “超重” 评级。最后，Piper Sandler 将 Inari Medical 的目标股价从 55.00 美元降至 50.00 美元，并在 5 月 1 日的报告中为该公司设定了 “中性” 评级。两位研究分析师给予该股票持有评级，五位给予买入评级。根据 MarketBeat 的数据，Inari Medical 的平均评级为 “中等买入”，平均目标股价为 65.71 美元。</p>
<p><strong>查看我们对 Inari Medical 的最新股票分析</strong></p>
<h2>Inari Medical 股价上涨 2.5%</h2>
<ul>
<li>3 家新上市公司的强劲股票图表</li>
</ul>
<p>NARI 股票周五开盘价为 48.15 美元。Inari Medical, Inc.的 12 个月最低价为 36.73 美元，最高价为 71.85 美元。公司的 50 天移动平均价格为 45.22 美元，其两百天移动平均价格为 50.59 美元。该公司的市值为 28 亿美元，市盈率为-117.44，贝塔系数为 1.02。</p>
<p>Inari Medical（纳斯达克股票代码：NARI - 获取免费报告）最近公布了其截至 4 月 30 日星期二的财报。公司报告该季度每股收益（EPS）为（0.26）美元，低于分析师预期的（0.11）美元。Inari Medical 的净利润率为-4.54%，净资产收益率为-1.65%。该季度公司营收为 1.4319 亿美元，超过分析师预期的 1.3832 亿美元。研究分析师平均预测，Inari Medical, Inc.本财年每股盈利将达到-0.41 美元。</p>
<h2>关于 Inari Medical（免费报告）</h2>
<p>Inari Medical, Inc 在美国为特定疾病状态制造微创、新颖和基于导管的机械血栓切除装置和配件。该公司提供 ClotTriever 系统，旨在核心、捕获和清除大血管中的大血栓，用于治疗深静脉血栓形成和外周血栓; FlowTriever 系统，一种大孔径导管式抽吸和机械血栓切除系统，用于清除外周血管中的大血栓，治疗肺栓塞和其他复杂的静脉血栓栓塞病例; InThrill 系统用于治疗小血管血栓; LimFlow 系统用于患有慢性威胁性肢体缺血且无适当的血管内或外科再灌注选择以及面临重大截肢风险的患者。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们比 Inari Medical 更喜欢的股票</li>
<li>什么是 WallStreetBets 以及他们瞄准哪些股票？</li>
<li>高通股票：尽管波动性，但以人工智能为动力的增长</li>
<li>什么是看跌期权成交量？</li>
<li>Salesforce 股票：会议总结，人工智能重点和预测</li>
<li>揭示 VWAP 的力量：交易者的关键指标</li>
<li>CAVA 是否过度估值？仔细研究这只高飞股</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TkFSSQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TkFSSQ"/></p>
<p><em>这则即时新闻警报是由 MarketBeat 的叙事科技和金融数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<p>→ 乔·拜登的终结（来自 Banyan Hill Publishing）(广告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTk5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTk5"/></p>
<h2>现在是否值得投资 $1,000 到 Inari Medical？</h2>
<p>在考虑 Inari Medical 之前，您会想听听这个。</p>
<p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉客户现在购买的股票清单... 而 Inari Medical 不在其中。</p>
<p>虽然 Inari Medical 目前在分析师中有 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

NARI

<p>根据最近向美国证券交易委员会提交的文件显示，Vanguard Group Inc.在第四季度增加了对 Inari Medical, Inc.的持股比例达 6.9%。其他对冲基金和机构投资者也增加了对该公司的持股。内部人士在过去 90 天内大量出售了公司股票。分析师们对 Inari Medical 发布了各种价格目标和评级</p>

<p>Vanguard Group Inc. lifted its position in Inari Medical, Inc. (NASDAQ:NARI - Free Report) by 6.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,038,292 shares of the company's stock after acquiring an additional 325,586 shares during the period. Vanguard Group Inc. owned 8.69% of Inari Medical worth $327,086,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p>
<div class="lb-trans"><p>Vanguard Group Inc.（万得集团）在第四季度增持了 Inari Medical, Inc.（纳斯达克股票代码：NARI - 免费报告）的持股比例，根据该公司最近向证券交易委员会（SEC）提交的文件。该公司在该时期收购了额外的 325,586 股股票后，拥有了 5,038,292 股公司股票。截至最近一次提交给 SEC 的文件，Vanguard Group Inc.拥有 Inari Medical 价值 3.27086 亿美元的股份，占公司总股本的 8.69%。</p>
</div><p>Get <strong>Inari Medical</strong> alerts:</p>
<ul>
<li>5 medical stocks growing earnings by triple digits</li>
</ul>
<div class="lb-trans"><p>获取 <strong>Inari Medical</strong> 的警报：</p>
<ul>
<li>5 家增长三位数收益的医疗股</li>
</ul>
</div><p>Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Norges Bank acquired a new position in shares of Inari Medical in the fourth quarter valued at about $29,491,000. Brown Advisory Inc. increased its holdings in Inari Medical by 17.6% in the 4th quarter. Brown Advisory Inc. now owns 1,702,113 shares of the company's stock worth $110,501,000 after buying an additional 255,182 shares during the period. Clearbridge Investments LLC purchased a new position in Inari Medical during the 4th quarter worth approximately $11,479,000. Point72 Europe London LLP lifted its stake in Inari Medical by 91.8% during the 4th quarter. Point72 Europe London LLP now owns 332,202 shares of the company's stock valued at $21,567,000 after acquiring an additional 158,997 shares during the period. Finally, Principal Financial Group Inc. boosted its holdings in shares of Inari Medical by 23.4% in the 4th quarter. Principal Financial Group Inc. now owns 567,266 shares of the company's stock valued at $36,827,000 after acquiring an additional 107,622 shares during the last quarter. Hedge funds and other institutional investors own 90.98% of the company's stock.</p>
<div class="lb-trans"><p>其他对冲基金和其他机构投资者最近也增加或减少了对该公司的持股。挪威中央银行在第四季度收购了 Inari Medical 股票的新头寸，价值约 2,949,100 美元。Brown Advisory Inc.在第四季度将其对 Inari Medical 的持股增加了 17.6%。Brown Advisory Inc.现在拥有 1,702,113 股公司股票，价值 1.10501 亿美元，比购买时增加了 255,182 股。Clearbridge Investments LLC 在第四季度购入了 Inari Medical 的新头寸，价值约 1,147,900 美元。Point72 Europe London LLP 在第四季度将其对 Inari Medical 的持股增加了 91.8%。Point72 Europe London LLP 现在拥有 332,202 股公司股票，价值 2,156,700 美元，比购买时增加了 158,997 股。最后，Principal Financial Group Inc.在第四季度增加了对 Inari Medical 的持股，增幅为 23.4%。Principal Financial Group Inc.现在拥有 567,266 股公司股票，价值 3,682,700 美元，比上一季度增加了 107,622 股。对冲基金和其他机构投资者拥有公司股份的 90.98%。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部人员活动</h2>
</div><p>In related news, CFO Mitch C. Hill sold 6,000 shares of the company's stock in a transaction dated Friday, April 12th. The shares were sold at an average price of $40.96, for a total transaction of $245,760.00. Following the completion of the transaction, the chief financial officer now owns 181,294 shares in the company, valued at approximately $7,425,802.24. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, CFO Mitch C. Hill sold 6,000 shares of the business's stock in a transaction that occurred on Friday, April 12th. The stock was sold at an average price of $40.96, for a total transaction of $245,760.00. Following the completion of the sale, the chief financial officer now directly owns 181,294 shares in the company, valued at $7,425,802.24. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Also, CEO Andrew Hykes sold 3,000 shares of the firm's stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $50.00, for a total value of $150,000.00. Following the completion of the transaction, the chief executive officer now owns 465,474 shares in the company, valued at approximately $23,273,700. The disclosure for this sale can be found here. Insiders have sold a total of 161,224 shares of company stock worth $7,514,191 over the last 90 days. 10.60% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>据相关消息，首席财务官 Mitch C. Hill 在 4 月 12 日星期五进行了一笔交易，卖出了公司股票 6,000 股。这些股票的平均价格为 40.96 美元，交易总额为 245,760.00 美元。交易完成后，首席财务官在公司中拥有 181,294 股股票，价值约 7,425,802.24 美元。该交易已在向 SEC 提交的法律文件中披露，可通过 SEC 网站访问。此外，首席财务官 Mitch C. Hill 在 4 月 12 日星期五进行了一笔交易，卖出了公司股票 6,000 股。这些股票的平均价格为 40.96 美元，交易总额为 245,760.00 美元。交易完成后，首席财务官直接持有公司 181,294 股股票，价值 7,425,802.24 美元。该交易已在提交给证券交易委员会的文件中披露，可通过 SEC 网站访问。此外，首席执行官 Andrew Hykes 在 5 月 28 日星期二进行了一笔交易，卖出了公司股票 3,000 股。这些股票的平均价格为 50.00 美元，交易总额为 150,000.00 美元。交易完成后，首席执行官在公司中持有 465,474 股股票，价值约 2,327,370.00 美元。此次交易的披露可在此处找到。内部人员在过去 90 天内共出售了价值 7,514,191 美元的公司股票共 161,224 股。公司内部人员目前持有公司股份的 10.60%。</p>
</div><h2>Analysts Set New Price Targets</h2>
<ul>
<li>After blowout earnings, Integer may be headed to new highs</li>
</ul>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
<ul>
<li>在业绩大幅增长后，Integer 可能将走向新高</li>
</ul>
</div><p>Several research analysts recently issued reports on NARI shares. Truist Financial reduced their target price on shares of Inari Medical from $61.00 to $52.00 and set a &#34;hold&#34; rating for the company in a report on Friday, March 22nd. Canaccord Genuity Group decreased their price objective on Inari Medical from $75.00 to $55.00 and set a &#34;buy&#34; rating for the company in a report on Wednesday, May 1st. Needham &amp; Company LLC lowered their target price on Inari Medical from $72.00 to $57.00 and set a &#34;buy&#34; rating on the stock in a research note on Wednesday, May 1st. Wells Fargo &amp; Company reduced their price target on Inari Medical from $100.00 to $84.00 and set an &#34;overweight&#34; rating for the company in a research report on Wednesday, May 1st. Finally, Piper Sandler decreased their price target on Inari Medical from $55.00 to $50.00 and set a &#34;neutral&#34; rating for the company in a report on Wednesday, May 1st. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Inari Medical has an average rating of &#34;Moderate Buy&#34; and an average price target of $65.71.</p>
<div class="lb-trans"><p>一些研究分析师最近发布了关于 NARI 股票的报告。Truist Financial 将 Inari Medical 的目标股价从 61.00 美元降至 52.00 美元，并在 3 月 22 日的报告中为该公司设定了 “持有” 评级。Canaccord Genuity Group 将 Inari Medical 的目标股价从 75.00 美元降至 55.00 美元，并在 5 月 1 日的报告中为该公司设定了 “买入” 评级。Needham &amp; Company LLC 将 Inari Medical 的目标股价从 72.00 美元降至 57.00 美元，并在 5 月 1 日的研究报告中为该股票设定了 “买入” 评级。富国银行将 Inari Medical 的目标股价从 100.00 美元降至 84.00 美元，并在 5 月 1 日的研究报告中为该公司设定了 “超重” 评级。最后，Piper Sandler 将 Inari Medical 的目标股价从 55.00 美元降至 50.00 美元，并在 5 月 1 日的报告中为该公司设定了 “中性” 评级。两位研究分析师给予该股票持有评级，五位给予买入评级。根据 MarketBeat 的数据，Inari Medical 的平均评级为 “中等买入”，平均目标股价为 65.71 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on Inari Medical</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Inari Medical 的最新股票分析</strong></p>
</div><h2>Inari Medical Trading Up 2.5 %</h2>
<ul>
<li>3 Newly Public Companies With Strong Charts Post-IPO</li>
</ul>
<div class="lb-trans"><h2>Inari Medical 股价上涨 2.5%</h2>
<ul>
<li>3 家新上市公司的强劲股票图表</li>
</ul>
</div><p>Shares of NARI stock opened at $48.15 on Friday. Inari Medical, Inc. has a 12-month low of $36.73 and a 12-month high of $71.85. The business's 50 day moving average is $45.22 and its two-hundred day moving average is $50.59. The company has a market capitalization of $2.80 billion, a P/E ratio of -117.44 and a beta of 1.02.</p>
<div class="lb-trans"><p>NARI 股票周五开盘价为 48.15 美元。Inari Medical, Inc.的 12 个月最低价为 36.73 美元，最高价为 71.85 美元。公司的 50 天移动平均价格为 45.22 美元，其两百天移动平均价格为 50.59 美元。该公司的市值为 28 亿美元，市盈率为-117.44，贝塔系数为 1.02。</p>
</div><p>Inari Medical (NASDAQ:NARI - Get Free Report) last announced its earnings results on Tuesday, April 30th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.15). Inari Medical had a negative net margin of 4.54% and a negative return on equity of 1.65%. The business had revenue of $143.19 million for the quarter, compared to analysts' expectations of $138.32 million. On average, research analysts predict that Inari Medical, Inc. will post -0.41 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Inari Medical（纳斯达克股票代码：NARI - 获取免费报告）最近公布了其截至 4 月 30 日星期二的财报。公司报告该季度每股收益（EPS）为（0.26）美元，低于分析师预期的（0.11）美元。Inari Medical 的净利润率为-4.54%，净资产收益率为-1.65%。该季度公司营收为 1.4319 亿美元，超过分析师预期的 1.3832 亿美元。研究分析师平均预测，Inari Medical, Inc.本财年每股盈利将达到-0.41 美元。</p>
</div><h2>About Inari Medical (Free Report)</h2>
<div class="lb-trans"><h2>关于 Inari Medical（免费报告）</h2>
</div><p>Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.</p>
<div class="lb-trans"><p>Inari Medical, Inc 在美国为特定疾病状态制造微创、新颖和基于导管的机械血栓切除装置和配件。该公司提供 ClotTriever 系统，旨在核心、捕获和清除大血管中的大血栓，用于治疗深静脉血栓形成和外周血栓; FlowTriever 系统，一种大孔径导管式抽吸和机械血栓切除系统，用于清除外周血管中的大血栓，治疗肺栓塞和其他复杂的静脉血栓栓塞病例; InThrill 系统用于治疗小血管血栓; LimFlow 系统用于患有慢性威胁性肢体缺血且无适当的血管内或外科再灌注选择以及面临重大截肢风险的患者。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than Inari Medical</li>
<li>What Is WallStreetBets and What Stocks Are They Targeting?</li>
<li>Qualcomm Stock: AI-Powered Growth Despite Volatility</li>
<li>What is Put Option Volume?</li>
<li>Salesforce Stock: Meeting Recap, AI Focus, and Forecast</li>
<li>Unveiling The Power Of VWAP: A Key Indicator For Traders</li>
<li>Is CAVA Overextended? A Closer Look at This High-Flying Stock</li>
</ul>
<div class="lb-trans"><h2>精选文章</h2>
<ul>
<li>五只我们比 Inari Medical 更喜欢的股票</li>
<li>什么是 WallStreetBets 以及他们瞄准哪些股票？</li>
<li>高通股票：尽管波动性，但以人工智能为动力的增长</li>
<li>什么是看跌期权成交量？</li>
<li>Salesforce 股票：会议总结，人工智能重点和预测</li>
<li>揭示 VWAP 的力量：交易者的关键指标</li>
<li>CAVA 是否过度估值？仔细研究这只高飞股</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TkFSSQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=NARI"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由 MarketBeat 的叙事科技和金融数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><p>→ The END of Joe Biden (From Banyan Hill Publishing)(Ad)</p>
<div class="lb-trans"><p>→ 乔·拜登的终结（来自 Banyan Hill Publishing）(广告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTk5" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8599&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Inari Medical right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资 $1,000 到 Inari Medical？</h2>
</div><p>Before you consider Inari Medical, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Inari Medical 之前，您会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inari Medical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉客户现在购买的股票清单... 而 Inari Medical 不在其中。</p>
</div><p>While Inari Medical currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Inari Medical 目前在分析师中有 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Inari Medical 公司（NASDAQ:NARI）的股票被先锋集团公司收购